Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Elisabeth Van Aken, Mérédis Favreau, Eva Ramboer, Kris Denhaerynck, Karen MacDonald, Ivo Abraham & Heidi Brié. (2020) Real-World Outcomes in Patients with Diabetic Macular Edema Treated Long Term with Ranibizumab (VISION Study). Clinical Ophthalmology 14, pages 4173-4185.
Read now
Read now
Mohammad Zarei, Ramak Roohipoor, Raziyeh Mahmoudzadeh, Mehdi Yaseri & Hamid Riazi-Esfahani. (2020) Epidemiology of Intravitreal Injections in Iran: Indications and Referral Patterns in a Tertiary Hospital. Clinical Ophthalmology 14, pages 1201-1206.
Read now
Read now
Christoph Kern, Johannes Schiefelbein, Dun Jack Fu, Benedikt Schworm, Dawn Sim, Tina Herold, Siegfried Priglinger & Karsten Kortuem. (2020) Two Year Visual Acuity and Structural Outcomes in Patients with Diabetic Macular Oedema Treated with Intravitreal Aflibercept – A Retrospective Cohort Study. Clinical Ophthalmology 14, pages 533-541.
Read now
Read now
Kanji Takahashi, Masahito Ohji, Hiroko Terasaki, Shigeru Honda, Philippe Margaron, Tadhg Guerin & Mitsuko Yuzawa. (2018) Efficacy and safety of ranibizumab monotherapy versus ranibizumab in combination with verteporfin photodynamic therapy in patients with polypoidal choroidal vasculopathy: 12-month outcomes in the Japanese cohort of EVEREST II study. Clinical Ophthalmology 12, pages 1789-1799.
Read now
Read now
Michael W. Stewart. (2016) Intravitreal anti-VEGF drug use in industrialized nations: why are newly introduced medications causing us to inject more and not less?. Current Medical Research and Opinion 32:12, pages 1951-1953.
Read now
Read now
Articles from other publishers (15)
Lorena Pérez-Gutiérrez & Napoleone Ferrara. (2023) Biology and therapeutic targeting of vascular endothelial growth factor A. Nature Reviews Molecular Cell Biology 24:11, pages 816-834.
Crossref
Crossref
Paul Mitchell, Prabhjot Juneja, Chao Wang & Rebecca Schnabel. (2022) Australian Pharmaceutical Benefits scheme data on utilisation of intravitreal therapy in retinal vein occlusion. Clinical & Experimental Ophthalmology 50:9, pages 1097-1100.
Crossref
Crossref
Terry Lee, Cason B. Robbins, Akshay S. Thomas & Sharon Fekrat. (2021) Treatment Patterns and Clinical Outcomes for Branch Retinal Vein Occlusion: An 8-Year Experience at a Tertiary Eye Center. Journal of VitreoRetinal Diseases 5:5, pages 412-419.
Crossref
Crossref
Philip Hykin, A Toby Prevost, Sobha Sivaprasad, Joana C Vasconcelos, Caroline Murphy, Joanna Kelly, Jayashree Ramu, Abualbishr Alshreef, Laura Flight, Rebekah Pennington, Barry Hounsome, Ellen Lever, Andrew Metry, Edith Poku, Yit Yang, Simon P Harding, Andrew Lotery, Usha Chakravarthy & John Brazier. (2021) Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT. Health Technology Assessment 25:38, pages 1-196.
Crossref
Crossref
Hong Xin, Nilima BiswasPin Li, Cuiling ZhongTamara C. Chan, Eric Nudleman & Napoleone Ferrara. (2021) Heparin-binding VEGFR1 variants as long-acting VEGF inhibitors for treatment of intraocular neovascular disorders. Proceedings of the National Academy of Sciences 118:21.
Crossref
Crossref
Ha-Lim Jeon, Hyesung Lee, Dongwon Yoon, Yeonkyung Lee, Jae Hui Kim, Donghyun Jee & Ju-Young Shin. (2020) Burden of diabetic macular oedema in patients receiving antivascular endothelial growth factor therapy in South Korea: a healthcare resource use and cost analysis. BMJ Open 10:12, pages e042484.
Crossref
Crossref
Manuel AP Vilela. (2020) Use of Anti-VEGF Drugs in Retinal Vein Occlusions. Current Drug Targets 21:12, pages 1181-1193.
Crossref
Crossref
Frank G. HolzMarta S. FigueroaFrancesco BandelloYit YangMasahito OhjiHong DaiHalina WykrotaSanjay SharmaCornelia Dunger-BaldaufSue Lacey, Wayne MacfaddenPaul Mitchell. (2020) RANIBIZUMAB TREATMENT IN TREATMENT-NAIVE NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina 40:9, pages 1673-1685.
Crossref
Crossref
Faris El-Dahiyat & Islam Eljilany. (2020) Cost-Minimization Analysis of Ranibizumab Versus Aflibercept for Treating Saudi Patients With Visual Impairment Owing to Age-Related Macular Degeneration or Diabetic Macular Edema. Value in Health Regional Issues 22, pages 23-26.
Crossref
Crossref
Jeannette Y. Stallworth, Akshay S. Thomas, Ryan Constantine, Sandra S. Stinnett & Sharon Fekrat. (2019) Treatment Patterns and Clinical Outcomes for Central Retinal Vein Occlusion in the Antivascular Endothelial Growth Factor Era. Journal of VitreoRetinal Diseases 4:1, pages 13-21.
Crossref
Crossref
Anna Kemp-Casey, Nicole Pratt, Emmae Ramsay & Elizabeth E. Roughead. (2018) Using Post-market Utilisation Analysis to Support Medicines Pricing Policy: An Australian Case Study of Aflibercept and Ranibizumab Use. Applied Health Economics and Health Policy 17:3, pages 411-417.
Crossref
Crossref
Masahiko Sugimoto, Hideyuki Tsukitome, Fumiki Okamoto, Tetsuro Oshika, Tetsuo Ueda, Masanori Niki, Yoshinori Mitamura, Hiroto Ishikawa, Fumi Gomi, Shigehiko Kitano, Hidetaka Noma, Masahiko Shimura, Shozo Sonoda, Osamu Sawada, Masahito Ohji, Kozo Harimoto, Masaru Takeuchi, Yoshihiro Takamura, Mineo Kondo & Taiji Sakamoto. (2018) Clinical preferences and trends of anti‐vascular endothelial growth factor treatments for diabetic macular edema in Japan. Journal of Diabetes Investigation 10:2, pages 475-483.
Crossref
Crossref
Donald S. FongTiffany Q. LuongRichard ContrerasJennifer J. JimenezPeter H. Custis, Vaishali PatelJoanna H. Campbell. (2018) TREATMENT PATTERNS AND 2-YEAR VISION OUTCOMES WITH BEVACIZUMAB IN DIABETIC MACULAR EDEMA. Retina 38:9, pages 1830-1838.
Crossref
Crossref
Abdullah Ozkaya, Mehmet Ozveren & Ali Demircan. (2018) The real life data of ranibizumab use among the diabetic macular edema patients in Turkey: Documenting the improvement with clinical optimization during three consecutive years. Saudi Journal of Ophthalmology 32:3, pages 175-179.
Crossref
Crossref
Oliver Reich, Martin K. Schmid, Roland Rapold, Lucas M. Bachmann & Eva Blozik. (2017) Injections frequency and health care costs in patients treated with aflibercept compared to ranibizumab: new real-life evidence from Switzerland. BMC Ophthalmology 17:1.
Crossref
Crossref